Site Content
Progenicyte's Retinal Amyloid Detection
Progenicyte Therapeutics, Inc. is at the forefront of developing non-invasive diagnostic tools for early detection of neurodegenerative diseases. One of our key innovations is the Retinal Amyloid Detection technology, which focuses on identifying amyloid-beta deposits in the retina—a biomarker closely associated with Alzheimer's disease.
The retina, sharing embryonic origins with the brain, mirrors cerebral pathological changes. Studies have demonstrated that retinal amyloid deposition correlates with brain amyloid levels, making the eye a valuable window for detecting neurological conditions. Our approach utilizes advanced retinal imaging techniques to detect these deposits, offering a non-invasive, cost-effective alternative to traditional methods like positron emission tomography (PET) scans.
By enabling earlier and more accessible detection of amyloid pathology, our Retinal Amyloid Detection technology aims to facilitate timely intervention and improve outcomes for individuals at risk of Alzheimer's and other neurodegenerative diseases. This innovation underscores Progenicyte's commitment to transforming diagnostic paradigms and enhancing patient care through cutting-edge scientific advancements.
Contact Us
If you have any questions or would like to know more about our company and our products, please do not hesitate to contact us.
Key Advantages of Progenicyte's Retinal Amyloid Detection
- Unmatched Specificity: Direct Aβ targeting for reliable detection.
- Non-Invasive and Rapid: Comfortable, real-time imaging.
- Cost-Efficient: Uses standard equipment with low operational costs.
- AI-Driven Accuracy: Enhanced detection with proprietary algorithms.
- Scalable: Simple integration into routine ophthalmology clinics.
- Regulatory-Ready: Strong IP with a clear path for FDA diagnostic approvals.
Our Partners
